Other studies have shown that activation of the PPARα–FGF21 pathway has protective effects against lipid accumulation and NAFLD and NASH development (Marino et al., 2016; Zeng et al., 2017). This evidence concerns the gene PPARA and metabolic dysfunction-associated steatotic liver disease.